Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
Frontline Axi-Cel Elicits 74% CR Rate in High-Risk Large B-Cell Lymphoma
Axicabtagene ciloleucel elicited a high objective response rate of 85%, with a complete response rate of 74% when used as a first-line therapy in patients with high-risk large B-cell lymphoma.
Relapsed/Refractory DLBCL Undergoes Rapid Evolution With CAR T-Cell Therapy, ADC...
High-dose chemotherapy and transplant remains the second-line standard of care for the majority of patients with relapsed/refractory diffuse large B-cell lymphoma; however, CAR T-cell therapy and other novel agents, which have transformed the third-line setting, may offer alternative and more personalized second-line options in the coming years.
Multi-Agent Therapy May Overcome CAR T Resistance in B-Cell Malignancies
Treatment with chimeric antigen receptor T-cells has induced unprecedented overall response rates and complete response rates in patients with relapsed/refractory B cell malignancies.
Promising 5-Year Outcomes Shown With CAR T-Cell Therapy in R/R B-Cell Lymphoma
For the treatment of relapsed or refractory aggressive B-cell lymphomas, chimeric antigen receptor–modified T-cell therapy is becoming more widely used. Still, little is known about outcomes for patients who receive CAR-modified T-cell therapy beyond 2 years.
Optimizing care with CAR T-cell therapy now and in the future for patients with ...
Get an update on chimeric antigen receptor (CAR) T-cell therapy for B-cell malignancies, including guidance on referral and toxicity management, in these interviews with five experts.
Off-the-Shelf NK Immunotherapy With Chemotherapy and Transplant Shows Early Acti...
Cord blood–derived natural killer (NK) immunotherapy, when paired with high-dose chemotherapy and autologous stem cell transplant (ASCT), showcased early antitumor activity in patients with B-cell non-Hodgkin lymphoma (NHL), according to data from a phase 2 trial (NCT03019640) presented in a poster during the 2021 Transplant & Cellular Therapy Meetings.
Dr. Solomon on the Effects of Liso-Cel in Prior Anti-CD19 Therapy–Treated B-NHL
Scott R. Solomon, MD, discusses the effects of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell non-Hodgkin lymphoma who were previously treated with CD19-directed therapies.
Can BiTE Molecules Make Off-the-Shelf Immuno-Oncology a Reality?
In hematologic malignancies, a new class of molecules is emerging that may ultimately offer clinical benefits comparable to those chimeric antigen receptor T-cell therapies while reducing some of the negatives associated with them.
FDA approves cell-based gene therapy to treat adults with relapsed or refractory...
Today, the U.S. Food and Drug Administration approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment.
Liso-Cel Responses Not Impacted By Prior Anti-CD19 Therapy in Relapsed/Refractor...
Prior exposure to anti-CD19 therapy did not impact response to the CAR T-cell therapy lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.